Streptokinase Loading in Liposomes for Vascular Targeted Nanomedicine Applications: Encapsulation Efficiency and Effects of Processing

Abstract

Vascular diseases leading to thrombo-occlusion are the leading cause of morbidity and mortality worldwide. Revascularization and restoration of antegrade blood flow is critical for tissue survival and patient health. In this aspect, systemic administration of thrombolytics (e.g., streptokinase) to dissolve occlusive thrombi is a clinically established strategy. However, this strategy typically necessitates the administration of large doses, leading to a high incidence of hemorrhagic complications due to systemic side effects. To minimize this risk, liposomes specifically targeted to the site of thrombo-occlusion have been bioengineered by exploiting ligand–receptor relationships pertinent to thrombus-associated cell phenotypes. This study focuses on encapsulating streptokinase within these liposomes, specifically regarding the effect of liposome processing conditions on streptokinase encapsulation and activity. Theoretical calculations of encapsulation capacity agreed well with that reported in the literature. The experimental encapsulation efficiency values are 45.9 ± 34.0% (n = 9 ± SD) and 21.6 ± 30.0% (n = 6 ± SD), using two different methods. The liposome processing conditions are found to decrease streptokinase activity; however, over 30% remain active after processing, maintaining enough activity to be therapeutic especially when protected inside a vehicle targeted to the site of thrombo-occlusion. The insight gained from the research reported here would enable refining the design and the processing conditions of liposomal formulations of fibrinolytics to yield reduced variability in encapsulation efficiency and streptokinase activity. The design of a thrombus-targeted ‘stealth’ liposome reported earlier and the current findings of fibrinolytics' encapsulation and activity in such liposomes can be efficiently integrated to develop an efficient strategy for vascular nanomedicine.

Keywords

streptokinase liposome encapsulation efficiency processing vascular nanomedicine

Get full access to this article

View all access options for this article.

References

Lloyd-Jones

Adams

Carnethon

. Heart Disease and Stroke Statistics – 2009 Update, Circulation, 2009: 119: e21–e181.

American Heart Association. (2008). Heart Disease and Stroke Statistics – 2008 Update, Dallas, Texas, American Heart Association.

Rosamond

Flegal

Furie

. Heart Disease and Stroke Statistics – 2008 Update, Circulation, 2008: 117: e25–e146.

Weisel

J.W.

Collet

J.-P

. Packaging is Important: Accelerated Thrombolysis with Encapsulated Plasminogen Activators, J. Thromb. Haemost., 2004: 2: 1545–1547.

Schömig

Kastrati

Dirschinger

. Coronary Stenting Plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction, N. Engl. J. Med., 2009: 343: 385–391.

The GUSTO Angiographic Investigators. The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction, N. Engl. J. Med., 1994: 330: 516.

Zijltra

Hoorntje

J.C.A.

de Boer

M.J.

. Long-Term Benefit of Primary Angioplasty as Compared with Thrombolytic Therapy for Acute Myocardial Infarction, N. Engl. J. Med., 1999: 341: 1413–1419.

Sezer

Oflaz

Gören

. Intracoronary Streptokinase after Primary Percutaneous Coronary Intervention, N. Engl. J. Med., 2007: 356: 1823–1834.

The Mutlicenter Acute Acute Stroke Trial – Europe Study Group. Thrombolytic Therapy with Streptokinase in Acute Ischemic Stroke, N. Engl. J. Med., 1996: 335: 145–150.

10.

Alexandrov

A.V.

Molina

C.A.

Grotta

J.C.

. Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke, N. Engl. J. Med., 2004: 351: 2170–2178.

11.

Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the Management of Lower Limb Peripheral Arterial Occlusion – A Consensus Document, J. Vasc. Interv. Radiol., 2003: 7: S337–S349.

12.

13.

Fujise

Revelle

B.M.

Stacy

. A Tissue Plasminogen Activator/P-Selectin Fusion Protein is an Effective Thrombolytic Agent, Circulation, 1997: 95: 715–722.

14.

The GUSTO Investigators. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction, N. Engl. J. Med., 1993: 329: 673–682.

15.

Cornett

Ocava

L.C.

Singh

Malhotra

Rosenbaum

D.M

. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke, Cardiol. Clin., 2008: 26: 251–265.

16.

Banerjee

Chisti

Banerjee

U.C

. Streptokinase – A Clinically Useful Thrombolytic Agent, Biotechnol. Adv., 2004: 22: 287–307.

17.

Damaschun

Gast

. Streptokinase is a Flexible Multi-Domain Protein, Eur. Biophys. J., 1992: 20: 355–361.

18.

Lee

H.S

. How Safe is the Readministration of Streptokinase? Drug Saf., 1995: 13(2): 76–80.

19.

Jennings

. Antibodies to Streptokinase, BMJ., 1996: 312: 393–394.

20.

Bode

Meinhardt

Runge

M.S.

. Platelet-Targeted Fibrinolysis Enhances Clot Lysis and Inhibits Platelet Aggregation, Circulation, 1991: 84: 805–813.

21.

Campbell

E.E.

Shifman

M.A.

Lewis

J.G.

Pasqua

J.J.

Pizzo

S.V.

A Colorimetric Assay for Releasable Plasminogen Activator, Clin. Chem., 1982: 28: 1125–1128.

22.

Rouf

S.A.

Moo-Young

Chisti

. Tissue-Type Plasminogen Activator Characteristics, Applications and Production Technology, Biotechnol. Adv., 1996: 14: 239–266.

23.

Schieman

Cohen

B.M.

Kozina

. Intracoronary Urokinase for Intracoronary Thrombus Accumulation Complicating Percutaneous Transluminal Coronary Angioplasty in Acute Ischemic Syndromes, Circulation, 1990: 82: 2052–2060.

24.

Mitchel

J.F.

Fram

D.B.

Palme

D.F.

. Enhanced Intracoronary Thrombolysis with Urokinase Using a Novel, Local Drug Delivery System, Circulation, 1995: 91: 785–793.

25.

McNamara

T.O.

Fischer

J.R

. Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase, Am. J. Roentgenol., 1985: 144: 769–775.

26.

Verhaeghe

. Thrombolysis in Arterial Occlusion, Thromb. Haemost., 1999: 82: 109–111.

27.

Valji

Roberts

A.C.

Davis

G.B.

Bookstein

J.J

. Pulsed-Spray Thrombolysis of Arterial and Bypass Graft Occlusions, Am. J. Roentgenol., 1991: 156: 617–621.

28.

Kandarpa

Drinker

P.A.

Singer

S.J.

Caramore

. Forceful Pulsatile Local Infusion of Enzyme Accelerates Thrombolysis: In Vivo Evaluation of a New Delivery System, Radiology, 1988: 168: 739–744.

29.

Eccleston

D.S.

Lincoff

A.M

. Catheter-Based Drug Delivery for Restenosis, Adv. Drug. Del. Rev., 1997: 24: 31–43.

30.

Mahmud

Keramati

. Highlights of the 2003 Transcatheter Cardiovascular Therapeutics Annual Meeting: Clinical Implications, J. Am. Coll. Cardiol., 2004: 43: 684–690.

31.

Mackman

. Triggers, Targets, and Treatments for Thrombosis, Nature, 2008: 451: 914–918.

32.

Tanabe

Regar

Lee

C.H.

. Local Drug Delivery Using Coated Stents: New Developments and Future Perspective, Curr. Pharm. Des., 2004: 10: 357–367.

33.

Fattori

Piva

. Drug-Eluting Stents in Vascular Intervention, Lancet, 2003: 361: 247–249.

34.

Schwartz

R.S.

Chronos

N.A.

Virmani

. Preclinical Restenosis Models and Drug-Eluting Stents: Still Important, Still Much To Learn, J. Am. College of Cardiol., 2004: 44: 1373–1385.

35.

Guzman

L.A.

Labhasetwar

Song

. Local Intraluminal Infusion of Biodegradable Polymeric Manoparticles. A novel Approach for Prolonged Drug Delivery after Balloon Angioplasty, Circulation, 1996: 94: 1441–1448.

36.

Song

Labhasetwar

Cui

Underwood

Levy

R.J

. Arterial Uptake of Biodegradable Nanoparticles for Intravascular Local Drug Delivery: Results with an Acute Dog Model, J. Control. Release., 1998: 54: 201–211.

37.

Labhasetwar

Song

Humphrey

Shebuski

Levy

R.J

. Arterial Uptake of Biodegradable Nanoparticles: Effect of Surface Modifications, J. Pharm. Sci., 1998: 87: 1229–1234.

38.

Labhasetwar

Song

Levy

R.J

. Nanoparticle Drug Delivery for Restenosis. Adv. Drug. Del. Rev., 1997: 24: 63–85.

39.

Fernandes

E.G.R.

de Queiroz

A.A.A.

Abraham

G.A.

Roman

J.S

. Antithrombogenic Properties of Bioconjugate Streptokinase-Polyglycerol Dendrimers, J. Mater. Sci. Mater. Med., 2006: 17: 105–111.

40.

Leach

J.K.

O’Rear

E.A.

Patterson

Miao

Johnson

A.E

. Accelerated Thrombolysis in a Rabbit Model of Carotid Artery Thrombosis with Liposome-Encapsulated and Microencapsulate Streptokinase, Thromb. Haemost., 2003: 90: 64–70.

41.

Leach

J.K.

Patterson

O’Rear

E.A

. Distributed Intraclot Thrombolysis: Mechanism of Accelerated Thrombolysis with Encapsulated Plasminogen Activators, J. Thromb. Haemost., 2004: 2: 1548–1555.

42.

Couto

L.T.

Donato

J.L.

de Nucci

. Analysis of Five Streptokinase Formulations Using the Euglobulin Lysis Test and the Plasminogen Activation Assay, Braz. J. Biol. Res., 2004: 37: 1889–1894.

43.

Chen

Zhang

. Functional Properties of a Novel Mutant of Staphylokinase with Platelet-Targeted Fibrinolysis and Antiplatelet Aggregation Activities, Eur. J. Pharmacol., 2007: 566: 137–144.

44.

Leach

J.K.

Patterson

O’Rear

E.A

. Encapsulation of a Plasminogen Activator Speeds Reperfusion, Lessens Infarct and Reduces Blood Loss in a Canine Model of Coronary Artery Thrombosis, Thromb. Haemost., 2004: 91: 1213–1218.

45.

Nguyen

P.D.

O'Rear

E.A.

Johnson

A.E.

Patterson

Whitsett

T.L.

Bhakta

. Accelerated Thrombolysis and Reperfusion in a Canine Model of Myocardial Infarction by Liposomal Encapsulation of Streptokinase, Circ. Res., 1990: 66: 875–878.

46.

Kaye

S.B

. Liposomes – Problems and Promise as Selective Drug Carriers, Cancer Treat. Rev., 1981: 8: 27–50.

47.

Lian

R.J.Y

. Trends and Developments in Liposome Drug Delivery Systems, J. Pharm. Sci., 2001: 90: 667–680.

48.

Ulrich

A.S

. Biophysical Aspects of Using Liposomes as Delivery Vehicles, Biosci. Rep., 2002: 22: 129–146.

49.

Langer

. Drug Delivery and Targeting, Nature, 1998: 392: 5–10.

50.

Bergstrand

Edwards

. Aggregate Structure in Dilute Aqueous Dispersions of Phospholipids, Fatty Acids and Lysophopholipids, Langmuir, 2001: 17: 3245–3253.

51.

Johnson

Bergstrand

Stalgren

J.J.R.

Edwards

. Adsorption of a PEO-PPO-PEO Triblock Copolymer on Small Unilaminar Vesicles: Equilibrium and Kinetic Properties and Correlation with Membrane Permeability, Langmuir, 2001: 17: 3902–3911.

52.

Garg

Dutta

Jain

N.K

. Reduced Hepatic Toxicity, Enhanced Cellular Uptake and Altered Pharmacokinetics of Stavudine Loaded Galactosylated Liposomes, Eur. J. Pharm. Biopharm., 2007: 67: 76–85.

53.

Nishiya

Sloan

. Interaction of RGD Liposomes with Platelets, Biochem. Biophys. Res. Commun., 1996: 224: 242–245.

54.

Huang

Zhou

Srinivasan

. Affinity Manipulation of Surface-Conjugated RGD Peptide to Modulate Binding of Liposomes to Activated Platelets, Biomaterials, 2008: 29: 1676–1685.

55.

Khalil

I.A.

Kogure

Futaki

Harashima

. Octaarginine-Modified Liposomes: Enhanced Cellular Uptake and Controlled Intracellular Trafficking, Int. J. Pharm., 2008: 354: 39–48.

56.

Tiukinhoy-Laing

S.D.

Huang

Klegerman

Holland

C.K.

McPherson

D.D

. Ultrasound-Facilitated Thrombolysis Using Tissue-Plasminogen Activator-Loaded Echogenic Liposomes, Thromb. Res., 2007: 119: 777–784.

57.

Suzuki

Takizawa

Negishi

Utoguchi

Maruyama

. Effective Gene Delivery with Novel Liposomal Bubbles and Ultrasonic Destruction Technology, Int. J. Pharm., 2008: 354: 49–55.

58.

Marsh

J.N.

Pan

. Fibrin-targeted Thrombolytic Therapy Using Acoustically Reflective Perfluorocarbon Nanoparticles, IEEE Ultrasonics Symposium, 2005: 2: 992–995.

59.

Sen Gupta

Huang

Lestini

B.J.

Sagnella

Kottke-Marchant

Marchant

R.E

. RGD-Modified Liposomes Targeted to Activated Platelets as a Potential Vascular Drug Delivery System, Thromb. Haemost., 2005: 95: 106–114.

60.

Colletier

J.-P.

Chaize

Winterhalter

Founier

. Protein Encapsulation in Liposomes: Efficiency Depends on Interactions between Protein and Phospholipid Bilayer, BMC Biotechnol., 2002: 2: 9–16.

61.

Schnyder

. and Huwyler, J. Drug Transport to Brain with Targeted Liposomes, NeuroRx, 2005: 2: 99–107.

62.

Azuaga

A.I.

Dobson

C.M.

Mateo

P.L.

Conejero-Lara

Unfolding and Aggregation During the Thermal Denaturation of Streptokinase, Eur. J. Biochem., 2002: 269: 4121–4133.

63.

Conejero-Lara

Parrado

Azuaga

A.I.

. Thermal Stability of the Three Domains of Streptokinase Studied by Circular Dichroism and Nuclear Magnetic Resonance, Protein Sci., 1996: 5: 2583–2591.

64.

Erdoğan

Özer

A.Y.

Volkan

Caner

Bilgili

. Thrombus Localization by Using Streptokinase Containing Vesicular Systems, Drug Deliv., 2006: 13: 303–309.

65.

Baek

S.-H.

Park

S.J.

Jin

S.-E.

Kim

J.-K.

Kim

C.-K.

Hwang

J.-M

. Subconjunctivally Injected, Liposome-Encapsulated Streptokinase Enhances the Absorption Rate of Subconjunctival Hemorrhages in Rabbits, Eur. J. Pharm. Biopharm., 2009: 72: 546–551.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB